Lantheus Holdings, Inc. (LNTH) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Lantheus Holdings, Inc.'s filing signal turned positive.

Lantheus Holdings is a radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products. Its portfolio is categorized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. The company's key commercial products include PYLARIFY for prostate cancer imaging, DEFINITY for echocardiography, and Neuraceq for Alzheimer's disease diagnostics. Lantheus operates primarily in the United States, with international sales through direct and third-party distribution and licensing agreements. The company's strategy involves expanding its commercial portfolio of innovative PET radiodiagnostics and advancing its pipeline of radiopharmaceuticals through strategic acquisitions and collaborations.

Revenue is primarily driven by the sales of its commercial products, PYLARIFY, DEFINITY, and Neuraceq. Additional revenue streams include royalties and milestone payments from strategic partnerships and contract development and manufacturing organization (CDMO) services.